EN | UA
EN | UA

Help Support

Back

Efficacy and safety of tenofovir amibufenamide vs. tenofovir disoproxil fumarate for chronic hepatitis B

Efficacy and safety of tenofovir amibufenamide vs. tenofovir disoproxil fumarate for chronic hepatitis B Efficacy and safety of tenofovir amibufenamide vs. tenofovir disoproxil fumarate for chronic hepatitis B
Efficacy and safety of tenofovir amibufenamide vs. tenofovir disoproxil fumarate for chronic hepatitis B Efficacy and safety of tenofovir amibufenamide vs. tenofovir disoproxil fumarate for chronic hepatitis B

A randomized clinical trial was performed to examine the efficacy and safety of tenofovir amibufenamide (TMF) and tenofovir disoproxil fumarate (TDF) for forty-eight weeks in individuals suffering from chronic hepatitis B.

See All

Key take away

A 48 weeks of treatment with tenofovir amibufenamide was non-inferior to tenofovir disoproxil fumarate in terms of anti-hepatitis B virus efficacy and demonstrated improved bone and renal safety.

Background

A randomized clinical trial was performed to examine the efficacy and safety of tenofovir amibufenamide (TMF) and tenofovir disoproxil fumarate (TDF) for forty-eight weeks in individuals suffering from chronic hepatitis B.

Method

In this double-blind, non-inferiority study, 1002 people with chronic hepatitis B were allocated to receive either 25 mg TMF or 300 mg TDF with a matching placebo. The percentage of people with hepatitis B virus DNA less than 20 IU/mL at week forty-eight was the major outcome ascertained. Assessment of safety (bone, renal and metabolic abnormalities) was also done.

Result

The baseline characteristics were well balanced between the groups. Following a median forty-eight weeks of therapy, the non-inferiority criterion was fulfilled in all the analysis sets. In the HBeAg-positive and HBeAg-negative population, the percentage of people who attained hepatitis B virus  DNA less than 20 IU/mL in the TMF and TDF groups, is illustrated in Table 1:


The TMF group exhibited considerably less reduction in bone mineral density at both spine and hip, and a smaller rise in serum creatinine at week forty-eight. The other safety findings were similar between the groups.

Conclusion

Regarding anti-hepatitis B virus efficacy, TMF exhibited non-inferiority to TDF.

Source:

Alimentary Pharmacology & Therapeutics

Article:

Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B

Authors:

Zhihong Liu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: